Homepage
Tera - Engineering resilience at the molecular scale

Anzen's platform combines proprietary enzyme reactor technology, enzyme immobilisation techniques, and AI-driven design to enable biochemical reactions outside living cells.
anzenindustries.comCrawled Nov 2, 2026
Tera - Engineering resilience at the molecular scale
Multiple catalysis-focused start-ups secure funding rounds to advance sustainable chemical processes. Eli Lilly partners with two biotech firms to develop novel drug candidates, leveraging their expertise in enzyme engineering and synthetic biology. The collaborations aim to accelerate therapeutic discovery using precision catalysis techniques.
Anzen Industries raises **$2.2 million** (£1.7m) in a pre-seed funding round to advance its **biomanufacturing and chemical engineering technology**. The deep tech startup leverages proprietary processes to develop scalable production methods for bio-based materials. Investors back its potential to disrupt traditional chemical synthesis with sustainable alternatives.
Anzen Industries secures $2.2 million in funding to advance its chemical production technology. The capital will support scaling operations, expanding infrastructure, and driving strategic growth. The startup focuses on innovative approaches to chemical manufacturing processes.
Anzen Industries secures £1.7 million in pre-seed funding to develop cell-free enzyme reactors for producing high-value chemicals. The round is led by investors LocalGlobe and Creator Fund. The technology aims to streamline biomanufacturing processes without relying on traditional cell-based methods.
UK-based deeptech startup **Anzen Industries** secures **$2.2 million in pre-seed funding** to advance chemical production innovation. The round is led by **LocalGlobe and Creator Fund**, with strategic angel investors from the UK, EU, and US, including **Konstantin von Unger** and **Cory Levy**. The funding supports the company’s focus on developing next-generation chemical manufacturing solutions.